ဤပေါ့ဒ်ကတ်စ် အကြောင်း 🔗

အစီအစဉ်တင်ဆက်သူများ:
အကြိမ်ရေကို အပ်ဒိတ်လုပ်ပါ။:
weekly
ပျမ်းမျှအသံအရှည်:
46 minutes
ဧည့်သည်အင်တာဗျူးများ
စပွန်ဆာတွေရှိတယ်။
အင်္ဂလိပ်
အမေရိကန်ပြည်ထောင်စု
89 ဖြစ်စဉ်များ
Jan. 16, 2025ကတည်းက
episodic

ပြီးခဲ့သည့် အပိုင်း 🔗

Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On th…

ပြီးခဲ့သည့် အပိုင်းများကို ရှာဖွေပါ

BackTable Tumor Board ၏ ယခင်အပိုင်းများကို ရှာဖွေပါ

ပြီးခဲ့သည့် အပိုင်းများ

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weeke…
When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan H…
How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope …
What options remain when a patient with microsatellite stable metastatic colorectal cancer (MSS mCRC) has progressed through every standard line of chemotherapy? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Sandra Algaze to explore the nuances of lat…
Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy acros…
How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal …
How should a breast cancer team manage central nervous system (CNS) disease now that systemic therapy, radiation, and surgery all compete for the first move? On this episode of BackTable Tumor Board, host Dr. Lindsay Peterson interviews Dr. Barbara O'Brien, neuro-oncologist at MD Anderson, about di…
How does delivering CAR-T in the community change patient care, and what has to happen next for these programs to scale? On this episode of the BackTable Tumor Board Podcast, host Aaron Lyss interviews Dr. Mike Byrne, hematologist at Tennessee Oncology and medical director for cellular therapy at O…
Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable Women’s Health, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveil…
မသက်ဆိုင်ကြောင်းရှင်းလင်းချက်: ဤစာမျက်နှာပေါ်တွင် ထည့်သွင်းထားသော ပေါ့တ်ကာစ်နှင့် အနုပညာလက်ရာများသည် ၎င်း၏ပိုင်ရှင်၏ပိုင်ဆိုင်မှုဖြစ်သည့် BackTable Inc. မှဖြစ်ပြီး Listen Notes, Inc နှင့် ဆက်နွှယ်ခြင်း သို့မဟုတ် ထောက်ခံထားခြင်းမရှိပါ။